Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

• Asıl Yazarlar: Anne Julienne Genuino (Yazar), Usa Chaikledkaew (Yazar), Anna Melissa Guerrero (Yazar), Thanyanan Reungwetwattana (Yazar), Ammarin Thakkinstian (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: BMC, 2019-11-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Background Breast cancer is the leading malignancy among Filipino women, with about 23.50% of cases characterized by human epidermal growth factor receptor-2 (HER2) overexpression. Trastuzumab, in addition to standard chemotherapy, is currently recommended as primary treatment for HER2-posi...